Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
91
-
Total 13F shares, excl. options
-
38.9M
-
Shares change
-
+7.51M
-
Total reported value, excl. options
-
$287M
-
Value change
-
+$36.7M
-
Number of buys
-
60
-
Number of sells
-
-26
-
Price
-
$7.39
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q4 2018
103 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q4 2018.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 91 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.9M shares
of 108M outstanding shares and own 35.9% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (5.89M shares), FRANKLIN RESOURCES INC (3.99M shares), BlackRock Inc. (3.62M shares), D. E. Shaw & Co., Inc. (2.28M shares), FMR LLC (2.06M shares), Sofinnova Investments, Inc. (1.91M shares), Broadfin Capital, LLC (1.88M shares), Vivo Capital, LLC (1.65M shares), MFN Partners Management, LP (1.5M shares), and Rock Springs Capital Management LP (1.33M shares).
This table shows the top 91 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.